ACIU ▲ +8.4% - AC Immune SA $ACIU - AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 AC Immune shares rose 8.4% following the company's announcement of positive safety and immunogenicity data at week-100 from Part 1 of its Phase 2 VacSYn trial evaluating ACI-7104, the company's vaccine candidate. The favorable safety profile and immune response results at this extended timepoint appear to have bolstered investor confidence in the program's advancement. 23-SEP-2026 07:00 AM ET